Attention deficit hyperactivity disorder in children, adolescents, and adults

CONTINUUM Lifelong Learning in Neurology

Volumn 15, Issue 6, 2009, Pages 78-97

  Schachar, Russell ^a  

^a NONE

Author keywords

And the patient's other relationships; Family members; It is important to assess the effect of attention deficit hyperactivity disorder (ADHD) on academic attainment and social relationships. Assessment should cover the effect of ADHD on the patient

Indexed keywords

AMFEBUTAMONE; ATOMOXETINE; CLOMIPRAMINE; CLONIDINE; DEXAMPHETAMINE; GUANFACINE; IMIPRAMINE; METHYLPHENIDATE; NORTRIPTYLINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ADOLESCENT; ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; BEHAVIOR THERAPY; CHILD; COGNITIVE THERAPY; COMORBIDITY; CONSTIPATION; DEPRESSION; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DROWSINESS; FATIGUE; HEART PALPITATION; HEART RATE; HUMAN; HYPERACTIVITY; HYPOTENSION; IMPULSIVENESS; LEARNING DISORDER; MENTAL DISEASE; NAUSEA; NEUROBIOLOGY; SEDATION; SIDE EFFECT; SWEATING; SYSTOLIC BLOOD PRESSURE; TREMOR; XEROSTOMIA;

EID: 78650749520     PISSN: 10802371     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.CON.0000348879.09070.21     Document Type: Article

References (52)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders: Fourth edition. Text revision. Washington, DC: American Psychiatric Association, 2000.
2. Barrickman LL, Perry PJ, Allen AJ, et al. Bupropion versus methylphenidate in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1995;34(5):649-657.
3. Biederman J, Baldessarini RJ, Goldblatt A, et al. A naturalistic study of 24-hour electrocardiographic recordings and echocardiographic findings in children and adolescents treated with desipramine [see comments]. J Am Acad Child Adolesc Psychiatry 1993;32(4):805-813.
4. Brassett-Harknett A, Butler N. Attention-deficit/hyperactivity disorder: an overview of the etiology and a review of the literature relating to the correlates and lifecourse outcomes for men and women. Clin Psychol Rev 2007;27(2):188-210.
5. Brehaut JC, Miller A, Raina P, McGrail KM. Childhood behavior disorders and injuries among children and youth: a population-based study. Pediatrics 2003;111(2):262-269.
6. Centers for Disease Control and Prevention (CDC). Mental health in the United States: prevalence of diagnosis and medication treatment for attention-deficit/hyperactivity disorder-United States, 2003. MMWR Morb Mortal Wkly Rep 2005;54(34):842-847.
7. Charach A, Figueroa M, Chen S, et al. Stimulant treatment over 5 years: effects on growth. J Am Acad Child Adolesc Psychiatry 2006;45(4):415-421.
8. Charach A, Ickowicz A, Schachar R. Stimulant treatment over five years: adherence, effectiveness, and adverse effects. J Am Acad Child Adolesc Psychiatry 2004;43(5):559-567.
9. de Graaf R, Kessler RC, Fayyad J, et al. The prevalence and effects of adult attention-deficit/hyperactivity disorder (ADHD) on the performance of workers: results from the WHO World Mental Health Survey Initiative. Occup Environ Med 2008; 65(12):835-842.
10. Dickstein DP, Garvey M, Pradella AG, et al. Neurologic examination abnormalities in children with bipolar disorder or attention-deficit/ hyperactivity disorder [published erratum appears in Biol Psychiatry 2006;15(60):418].
11. Biol Psychiatry 2005;58(7):517-524.
12. Faraone SV, Sergeant J, Gillberg C, Biederman J. The worldwide prevalence of ADHD: is it an American condition? World Psychiatry 2003;2(2):104-113.
13. Gehricke JG, Loughlin SE, Whalen CK, et al. Smoking to self-medicate attentional and emotional dysfunctions. Nicotine Tob Res 2007;9(suppl 4):523-536.
14. Goos LM, Crosbie J, Payne S, Schachar R. Validation and extension of the endophenotype model in ADHD patterns of inheritance in a family study of inhibitory control. Am J Psychiatry 2009;166(6):711-717.
15. Gould MS, Walsh BT, Munfakh JL, et al. Sudden death and use of stimulant medications in youths. Am J Psychiatry 2009:15.
16. Greenhill L, Kollins S, Abikoff H, et al. Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD [published erratum appears in J Am Acad Child Adolesc Psychiatry 2007;46(1):141].
17. J Am Acad Child Adolesc Psychiatry 2006;45(11):1284-1293.
18. Greenhill LL, Pliszka S, Dulcan MK, et al; American Academy of Child and Adolescent Psychiatry. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry 2002; 41(2 suppl):26-49.
19. HanćT, Cieślik J. Growth in stimulant-naive children with attention-deficit/hyperactivity disorder using cross-sectional and longitudinal approaches. Pediatrics 2008;121(4): e967-e974.
20. Hemmer SA, Pasternak JF, Zecker SG, Trommer BL. Stimulant therapy and seizure risk in children with ADHD. Pediatr Neurol 2001;24(2):99-102.
21. Hughes CW, Emslie GJ, Crismon ML, et al. Texas Children's Medication Algorithm Project: update from Texas Consensus Conference Panel on Medication Treatment of Childhood
22. Major Depressive Disorder. J Am Acad Child Adolesc Psychiatry 2007;46(6):667-686.
23. Ickowicz A. Bupropion-methylphenidate combination and grand mal seizures. Can J Psychiatry 2002;47(8):790-791.
24. Jadad A. The treatment of attention-deficit/hyperactivity disorder: an evidence report. Hamilton, Canada: McMaster University Evidence-based Practice Center, 1998:50.
25. Jensen PS, Hinshaw SP, Kraemer HC, et al. ADHD comorbidity findings from the MTA study: comparing comorbid subgroups. J Am Acad Child Adolesc Psychiatry 2001;40(2):147-158.
26. Jin C, Schachar R. Methylphenidate treatment of attention-deficit/ hyperactivity disorder secondary to traumatic brain injury: a critical appraisal of treatment studies. CNS Spectr 2004;9(3):217-226.
27. Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry 2006;163(4):716-723.
28. Kessler RC, Lane M, Stang PE, Van Brunt DL. The prevalence and workplace costs of adult attention deficit hyperactivity disorder in a large manufacturing firm. Psychol Med 2009;39(1):137-147.
29. Khan SA, Faraone SV. The genetics of ADHD: a literature review of 2005. Curr Psychiatry Rep 2006;8(5):393-397.
30. Knight M. Stimulant-drug therapy for attention-deficit disorder (with or without hyperactivity) and sudden cardiac death. Pediatrics 2007;119(1):154-155.
31. Kuntsi J, Neale BM, Chen W, et al. The IMAGE project: methodological issues for the molecular genetic analysis of ADHD. Behav Brain Funct 2006;2:27.
32. Kurlan R. Methylphenidate to treat ADHD is not contraindicated in children with tics. Mov Disord 2002;17(1):5-6.
33. Levin H, Hanten G, Max J, et al. Symptoms of attention-deficit/ hyperactivity disorder following traumatic brain injury in children. J Dev Behav Pediatr 2007;28(2):108-118. (Pubitemid 46624835)
34. Max JE, Schachar RJ, Levin HS, et al. Predictors of secondary attention-deficit/hyperactivity disorder in children and adolescents 6 to 24 months after traumatic brain injury. J Am Acad Child Adolesc Psychiatry 2005;44(10):1041-1049.
35. Mill J, Petronis A. Pre- and peri-natal environmental risks for attention-deficit hyperactivity disorder (ADHD): the potential role of epigenetic processes in mediating susceptibility. J Child Psychol Psychiatry 2008;49(10):1020-1030.
36. Miller AR, Brehaut JC, Raina P, et al. Use of medical services by methylphenidate-treated children in the general population. Ambul Pediatr 2004a;4(2):174-180.
37. Miller AR, Lalonde CE, McGrail KM. Children's persistence with methylphenidate therapy: a population-based study. Can J Psychiatry 2004b;49(11):761-768.
38. Miller AR, Lalonde CE, McGrail KM, Armstrong RW. Prescription of methylphenidate to children and youth, 1990-1996 [see comment]. CMAJ 2001;165(11):1489-1494.
39. Molina BS, Hinshaw SP, Swanson JM, et al; MTA Cooperative Group. The MTA at 8 years: prospective follow-up of children treated for combined-type ADHD in a multisite study. J Am Acad Child Adolesc Psychiatry 2009;48(5):484-500.
40. Niklasson L, Rasmussen P, Oskarsdó ttir S, Gillberg C. Autism, ADHD, mental retardation and behavior problems in 100 individuals with 22q11 deletion syndrome. Res Dev Disabil 2009;30(4):763-773.
41. Pearson DA, Santos CW, Roache JD, et al. Treatment effects of methylphenidate on behavioral adjustment in children with mental retardation and ADHD. J Am Acad Child Adolesc Psychiatry 2003;42(2):209-216.
42. Pliszka SR. Pharmacologic treatment of attention-deficit/hyperactivity disorder: efficacy, safety and mechanisms of action. Neuropsychol Rev 2007;17(1):61-72.
43. Reiersen AM, Todd RD. Co-occurrence of ADHD and autism spectrum disorders: phenomenology and treatment. Expert Rev Neurother 2008;8(4):657-669.
44. Shaw P, Lerch J, Greenstein D, et al. Longitudinal mapping of cortical thickness and clinical outcome in children and adolescents with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 2006;63(5):540-549.
45. Solanto MV. Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration. Behav Brain Res 1998;94(1):127-152.
46. Swanson J, Arnold LE, Kraemer H, et al; MTA Cooperative Group. Evidence, interpretation, and qualification from multiple reports of long-term outcomes in the Multimodal Treatment Study of children with ADHD (MTA): Part II: supporting details. J Atten Disord 2008;12(1):15-43.
47. Swanson JM, Elliott GR, Greenhill LL, et al. Effects of stimulant medication on growth rates across 3 years in the MTA follow-up. J Am Acad Child Adolesc Psychiatry 2007;46(8):1015-1027.
48. Thapar A, O'Donovan M, Owen MJ. The genetics of attention deficit hyperactivity disorder. Hum Mol Genet 2005;14(spec no. 2):275-282.
49. Valera EM, Faraone SV, Murray KE, Seidman LJ. Meta-analysis of structural imaging findings in attention-deficit/hyperactivity disorder. Biol Psychiatry 2007;61(12):1361-1369.
50. Vetter VL, Elia J, Erickson C, et al. Cardiovascular monitoring of children and adolescents with heart disease receiving stimulant drugs: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing. Circulation 2008;117(18):2407-2423.
51. Vitiello B, Towbin K. Stimulant treatment of ADHD and risk of sudden death in children. Am J Psychiatry 2009;166(9):955-957.
52. Woodward LJ, Fergusson DM, Horwood LJ. Driving outcomes of young people with attentional difficulties in adolescence. J Am Acad Child Adolesc Psychiatry 2000;39(5):627-634.